- Home
- ORKT vs TLSA Comparison
ORKT vs TLSA Comparison
Compare ORKT & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORKT
- TLSA
- Stock Information
- Founded
- ORKT 2003
- TLSA 2013
- Country
- ORKT Singapore
- TLSA United Kingdom
- Employees
- ORKT N/A
- TLSA N/A
- Industry
- ORKT
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- ORKT
- TLSA Health Care
- Exchange
- ORKT NYSE
- TLSA Nasdaq
- Market Cap
- ORKT 82.9M
- TLSA 87.8M
- IPO Year
- ORKT 2024
- TLSA 2000
- Fundamental
- Price
- ORKT $3.07
- TLSA $0.90
- Analyst Decision
- ORKT
- TLSA
- Analyst Count
- ORKT 0
- TLSA 0
- Target Price
- ORKT N/A
- TLSA N/A
- AVG Volume (30 Days)
- ORKT 2.7M
- TLSA 384.7K
- Earning Date
- ORKT 11-19-2024
- TLSA 12-27-2024
- Dividend Yield
- ORKT N/A
- TLSA N/A
- EPS Growth
- ORKT N/A
- TLSA N/A
- EPS
- ORKT N/A
- TLSA N/A
- Revenue
- ORKT $3,904,592.00
- TLSA N/A
- Revenue This Year
- ORKT N/A
- TLSA N/A
- Revenue Next Year
- ORKT N/A
- TLSA N/A
- P/E Ratio
- ORKT N/A
- TLSA N/A
- Revenue Growth
- ORKT N/A
- TLSA N/A
- 52 Week Low
- ORKT $1.45
- TLSA $0.41
- 52 Week High
- ORKT $8.00
- TLSA $1.74
- Technical
- Relative Strength Index (RSI)
- ORKT N/A
- TLSA 46.21
- Support Level
- ORKT N/A
- TLSA $0.88
- Resistance Level
- ORKT N/A
- TLSA $1.27
- Average True Range (ATR)
- ORKT 0.00
- TLSA 0.10
- MACD
- ORKT 0.00
- TLSA -0.00
- Stochastic Oscillator
- ORKT 0.00
- TLSA 10.00
About ORKT ORANGEKLOUD TECHNOLOGY INC
Orangekloud Technology Inc is a company that operates through its subsidiaries provide IT consultancy services and distribution of related products and services. The Company also offers ERPs predominately in Singapore. It derives revenue from platform subscriptions, license and products and professional services.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.